On May 5, 2026, HHS Secretary Robert F. Kennedy Jr. revealed an initiative aimed at regulating the prescribing practices of selective serotonin reuptake inhibitors (SSRIs), which are widely used antidepressants.
This move comes amid ongoing debates regarding the effectiveness and safety of antidepressants, as well as concerns about their widespread use in mental health treatment.
Additionally, the announcement coincides with Johnson & Johnson's promotion of a new drug intended for inflammatory bowel disease, highlighting the active role of pharmaceutical companies in the health sector.